Background: The use of prasugrel or ticagrelor as part of dual antiplatelet therapy with
acetylsalicylic acid after acute coronary syndrome (ACS) improves clinical outcomes relative …

Purpose Monotherapy with either aspirin or clopidogrel is recommended for long-term use
after discontinuation of dual-antiplatelet therapy (DAPT) for acute coronary syndrome (ACS) …

Objective: To evaluate the long-term cost-effectiveness of 12-months treatment with
prasugrel vs clopidogrel from four European healthcare systems' perspectives (Germany …

Background We aimed to compare the clinical outcomes of clopidogrel, prasugrel, and
ticagrelor in clinical practice using the National Cardiovascular Database ACTION …

What is known and objective Current guidelines recommend a combination of clopidogrel
and aspirin for management of patients who have experienced an acute coronary syndrome …

Abstract Background and Objective The economic outcomes of dual antiplatelet therapy in
East Asian patients are still unclear. We aimed to evaluate the economic outcomes of …

Objective To assess the long-term cost-effectiveness of 12 months treatment of prasugrel
compared to clopidogrel in patients with acute coronary syndrome (ACS) undergoing …

Background—In patients with acute coronary syndromes and planned percutaneous
coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by …

Background—On average, acute coronary syndrome patients treated with prasugrel
experience fewer ischemic complications, but more bleeding, than those receiving …

BACKGROUND: In patients with acute coronary syndrome (ACS) treated with percutaneous
coronary intervention (PCI), newer antiplatelet agents prasugrel and ticagrelor have lower …